Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.82 - $2.49 $307,500 - $933,750
-375,000 Reduced 41.67%
525,000 $1.02 Million
Q1 2023

May 12, 2023

SELL
$0.8 - $1.22 $1 Million - $1.53 Million
-1,255,100 Reduced 58.24%
900,000 $783,000
Q4 2022

Feb 07, 2023

BUY
$0.69 - $2.21 $1.49 Million - $4.76 Million
2,155,100 New
2,155,100 $2.14 Million

Others Institutions Holding XFOR

About X4 Pharmaceuticals, Inc


  • Ticker XFOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,646,096
  • Market Cap $23.3M
  • Description
  • X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...
More about XFOR
Track This Portfolio

Track Lynwood Capital Management Inc. Portfolio

Follow Lynwood Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynwood Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Lynwood Capital Management Inc. with notifications on news.